Rationale: Monocytes recruited to ischemic myocardium originate from a reservoir in the spleen, and the release from their splenic niche relies on angiotensin (Ang) II signaling.
A ngiotensin-converting enzyme (ACE) inhibitors, which lower systemic and tissue levels of angiotensin (Ang) II by reducing cleavage of the C-terminal dipeptide from Ang-1, were developed as antihypertensive agents. They have evolved into a mainstay of heart failure therapy; current guidelines recommend initiation of therapy early after myocardial infarction (MI), 1 and are based on clinical trials showing that ACE inhibition decreases mortality. 2 Initially, these effects were attributed to hemodynamic unloading of the left ventricle. 3 Subsequently, it became clear that ACE inhibitors also decrease hypertrophy and fibrosis through direct effects on heart tissue. 4 These well-described effects reduce left ventricular remodeling following MI, and therapy is therefore continued indefinitely.
The effect of ACE inhibitors on the monocyte response during the first week after MI is less well understood. There is emerging evidence that Ang II, which sharply increases in circulation after MI, is a proinflammatory peptide that closely interacts with the immune system, including monocytes. 4 -7 Furthermore, Ang II can modulate the regional cytokine milieu. 8 -11 It has recently been shown that 40% to 70% of monocytes acutely recruited to the infarct originate from a splenic reservoir. 6 In the steady state, monocytes reside in clusters of Ϸ50 cells in the subcapsular red pulp of the spleen. On interaction of Ang II with its cell surface receptor, Ang II type 1 receptor (AT 1 R), splenic monocytes increase their motility and intravasate into nearby splenic veins. In the mouse, this "emergency reservoir" releases up to 1 million monocytes within 24 hours after MI, 6 which are subsequently recruited into the infarct mainly via interaction of the chemokine MCP-1 with its cognate receptor CCR2. 12 The cells then assume a central role in orchestrating the healing wound. [13] [14] [15] [16] They promote removal of cell debris and extracellular matrix through proteolysis and phagocytosis and regulate tissue repair by stimulating angiogenesis and fibroblasts. However, an excessive inflammatory response is deleterious. In atherosclerotic apolipoprotein (apo)E Ϫ/Ϫ mice with coronary ligation, the coexisting systemic inflammation associated with hyperlipidemia increases levels of circulating monocytes and their recruitment to the infarct. 17 Consequently, scar healing is compromised and development of heart failure accentuated. 17, 18 In patients, increased levels of blood monocytes during MI also correlate with enhanced left ventricular dilation and adverse outcome. 19 -21 Here, we hypothesized that ACE inhibition reduces splenic release of monocytes, decreases their recruitment into the infarct, curbs excessive infarct inflammation, and promotes coordinated wound healing. We further propose that the effect of ACE inhibition on the innate immune system presents a new mechanism that at least partially explains the reduction of heart failure following MI.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Animal Models
Female C57BL/6J and apoE Ϫ/Ϫ mice were purchased from The Jackson Laboratory. Cx3cr1 GFP/ϩ mice were obtained by breeding Cx3cr1 GFP/GFP mice with C57BL/6J mice. Cx3cr1 GFP/ϩ mice have 1 Cx3cr1 allele replaced with cDNA encoding eGFP and can be used to track monocytes. 22 ApoE Ϫ/Ϫ mice had an average age of 45 weeks and were on a high-cholesterol diet. The institutional animal welfare committee approved the research reported.
MI, ischemia/reperfusion injury (IRI), and splenectomy were performed as described (see the Online Data Supplement). 6, 23 Mice were treated with a dose of 100 mg/kg 24, 25 enalapril daily for the acute studies (euthanasia 1 day after MI) or 20 mg/kg enalapril daily 26, 27 for the chronic studies. Treatment was initiated 2 days before MI and continued for 7 days thereafter. In additional cohorts, we initiated enalapril treatment 1 hour or 24 hours after coronary ligation. Hydralazine was given at a dose of 15 mg/kg 28 daily. Treatment was performed by gastric gavage.
Histology
Histology of spleens and hearts was assessed as described in the Online Methods.
Flow Cytometry
Mice were euthanized on days 1, 2, 3, and 5 after MI and 1 day after IRI for flow cytometry (nϭ3 to 5 mice per group and time point). Spleens, hearts, and blood were prepared and analyzed for total organ monocyte numbers by multicolor flow cytometry. 18
ELISA for Serum Ang II Levels
Ang II concentration in blood was determined with an Ang II ELISA.
Intravital Microscopy
Intravital microscopy of splenic monocytes was performed in Cx3cr1 GFP/ϩ mice. During isoflurane anesthesia, the spleen was exteriorized and imaged with a prototypic intravital laser scanning microscope (IV100, Olympus Corporation). 6, 29 
In Vitro Migration
Migration experiments using Ang II as a chemoattractant were performed using sorted monocytes from spleen. For the receptor blocking condition, cells were pretreated with the AT 1 R antagonist losartan.
Western for AT 1 R on Splenic Monocytes
Splenic monocytes were isolated by flow-activated cell sorting and dimerization of the AT 1 R was assessed by Western blotting.
Quantitative PCR
Infarct tissue was examined for expression of markers of inflammatory monocytes (Ly-6C), differentiated macrophages (CD68; Mac3), TNF-␣, TGF-␤, myeloperoxidase, and appropriate controls (GAPDH). TGF-␤ mRNA was also measured in monocytes isolated from the heart.
Fluorescence Molecular Tomography-X-Ray Computed Tomography
On day 1 after MI, we performed fluorescence molecular tomography (FMT-CT (fluorescence molecular tomography in conjunction with x-ray computed tomography) imaging 17, 30, 31 to interrogate the magnitude of inflammation 24 hours after injection of 5 nmol of a pan-cathepsin protease sensor (Prosense-680, PerkinElmer) in apoE Ϫ/Ϫ mice with and without enalapril treatment and apoE Ϫ/Ϫ mice that were splenectomized at the time of coronary ligation.
Magnetic Resonance Imaging
We performed in vivo MRI on day 21 after MI in apoE Ϫ/Ϫ mice with and without enalapril treatment and in apoE Ϫ/Ϫ mice that were splenectomized at the time of coronary ligation. 23
Ischemia/Reperfusion Injury
IRI was studied in wild-type mice, apoE Ϫ/Ϫ with and without enalapril treatment, and in apoE Ϫ/Ϫ that were splenectomized immediately before ischemia. The area at risk was assessed using fluorescent microspheres, and the resulting infarct size by triphenyltetrazolium chloride (TTC) staining.
Blood Pressure Measurements
Blood pressure was monitored using the noninvasive tail cuff method. 32
Statistics
Results are expressed as meansϮSEM. Statistical comparisons between 2 groups were evaluated by Student t test and corrected by ANOVA for multiple comparisons. A value of PϽ0.05 was considered statistically significant. 
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Results
ACE Inhibition Prevents the Release of Splenic Monocytes in Acute MI
Myocardial injury or administration of Ang II results in increased motility of monocytes in the spleen. 6 We therefore investigated whether lowering levels of Ang II through ACE inhibition impacts splenic monocytes. First, we assessed monocyte numbers in the spleen on day 1 after permanent coronary ligation with and without enalapril treatment. The subcapsular region is the site where monocytes are stored in the spleen. 6 Immunofluorescence staining for CD11b showed significant reduction of CD11b ϩ cells in the subcapsular region after MI. Treatment with enalapril completely abolished splenic loss of monocytes after MI (PϽ0.0001; Figure 1A ).
To quantify total monocyte numbers in the whole spleen, we used flow cytometry 1 day after coronary ligation. MI induced massive release of monocytes from the spleen. Monocyte numbers in spleens of mice with MI were reduced by 42% compared with spleens from naive mice ( Figure 1B ; Pϭ0.01). In contrast, infarcted mice treated with enalapril showed practically no release of splenic monocytes (no MI, 1.24ϫ10 6 monocytes per spleen; MI plus enalapril, 1.22ϫ10 6 monocytes per spleen; PϭNS; Figure 1B) . The effect was observed for both subsets, Ly6-C high as well as Ly6-C low monocytes.
Next we investigated if the effect on splenic monocytes was related to vasodilatory properties of ACE inhibitors. We confirmed that enalapril significantly reduced Ang II serum levels in plasma (PϽ0.05; Figure 1C ). We then treated mice with the direct vasodilator Hydralazine and chose a dose of 15 mg/kg/d, which had previously been shown to reduce systolic blood pressure to Ͻ80 mm Hg. 28 Flow cytometric analysis of the spleen showed that Hydralazine did not reduce the release of monocytes after MI (PϭNS versus untreated MI; Figure  1D ). We thus concluded that monocyte retention in the spleen by enalapril is likely not related to its vasodilatory properties, because lowering of blood pressure with a direct vasodilator did not reproduce its effect. Blood pressure data in various cohorts are shown in Online Table I .
ACE Inhibition Reduces the Motility of Splenic Monocytes
Next, we aimed to investigate how ACE inhibition reduces monocyte release from the spleen. We used time-lapse intravital microscopy, a technique that allows to track endogenous monocytes in the subcapsular red pulp of the spleen in live animals. 6 We investigated the spleens of Cx3cr1 GFP/ϩ mice, in which 1 Cx3cr1 allele is replaced with cDNA encoding eGFP. Thus, cells that express the fractalkine receptor are rendered GFP ϩ and can be followed with fluorescence imaging. Within the splenic capsule, 95% of the GFP ϩ cell population consists of monocytes, macrophages and dendritic cells. 6 The present study confirmed that splenic monocytes increase motility after MI (4-fold increase, PϽ0.01; Figure 2A and Online Movie I). Previously, it was shown that this increase in motility leads to intravasation into sinusoids and splenic veins and departure of the cells from the organ. 6 When treated with enalapril, monocytes did not increase motility after MI (Figure 2A and Online Movie I). Splenic macrophages or dendritic cells showed very low displacement and there was no difference between both groups, as expected ( Figure 2A ).
In vitro cell migration experiments corroborated the importance of Ang II signaling for monocyte motility. Ang II induced rigorous migration of monocytes isolated from the spleen; however, cotreatment with the AT 1 R antagonist losartan reduced this effect significantly ( Figure 2B ), suggesting that mobilization of splenic monocytes requires Ang II/AT 1 R signaling.
Next, we investigated dimeric forms of the AT 1 R on monocytes sorted from spleens by Western blot. Ang II/AT 1 R signaling requires dimerization and covalent crosslinking of the receptor, an event that can be quantified by Western blot using reduced gels. 6, 33 We found that MI triggers AT 1 R dimerization in splenic monocytes. However, enalapril reduced this effect ( Figure 2C ). These data describe the mechanism how ACE inhibition blocks splenic monocyte release: they indicate that ACE inhibition reduces Ang II/AT 1 R signaling in monocytes, which directly affects monocyte motility, and thus departure from the splenic reservoir. 
Blocking of the Splenic Monocyte Release Diminishes Recruitment to the Infarct
Reduced mobilization of splenic monocytes by enalapril should decrease accumulation of these cells in ischemic myocardium. Flow cytometry confirmed a marked reduction in the number of monocytes accumulating in the infarct on day 1, 3, and 5 after permanent coronary ligation ( Figure 3A ). The inflammatory response on day 1 after MI is dominated by Ly-6C high monocytes. 18 Accordingly, the impact of enalapril was more profound on this subset ( Figure 3A ). However, Ly-6C low monocyte numbers were also reduced in the heart, especially at later time points ( Figure 3A ). Immunoreactive staining for CD11b and MAC-3 confirmed that enalapril reduced the number of myeloid cells in 1-day-old infarcts ( Figure 3B ). The number of CD11b ϩ cells per high power field was reduced from 52Ϯ4 to 31Ϯ4 (PϽ0.01), and the area positive for MAC-3 from 5.8Ϯ0.7 to 3.5Ϯ0.4% (PϽ0.01).
Because some patients will not be receiving ACE inhibitor therapy before their first MI, we next tested the effects of enalapril 1 hour or 24 hours after coronary ligation. This experiment models the situation of a first MI, when treatment is initiated early after ischemia. The impact of ACE inhibition on monocyte flux was preserved, but somewhat attenuated when started with a 24-hour delay, probably because there was a period of uninhibited monocyte release after MI (Online Figure I) .
Quantitative PCR of infarct tissue showed that enalapril profoundly reduced expression of TGF-␤, myeloperoxidase, and TNF-␣ (Figure 4 ). MAC-3, CD68, and Ly-6C, which are genes primarily expressed by inflammatory monocytes and macrophages, were also reduced ( Figure 4 ). Furthermore, we assessed the mRNA level of TGF-␤ in monocytes that were isolated by flow-activated cell sorting and found levels that were 4.3-fold higher than in infarct tissue (PϽ0.01 versus infarct tissue). Thus, we concluded that monocytes may be a source of TGF-␤ after MI. 
ACE Inhibition Reduces Inflammation in Infarcts of ApoE ؊/؊ Mice
We next tested whether inhibiting the mobilization of the splenic monocyte reservoir affects cardiac wound healing. We chose to investigate infarct healing in apoE Ϫ/Ϫ mice, because their heightened systemic inflammation, specifically the increased availability of monocytes in circulation, may resemble patients with atherosclerosis better. 17 This model is particularly helpful when innate immune responses to ischemia and tissue repair are studied. 34 Flow cytometric analysis of apoE Ϫ/Ϫ mice on day 1 after permanent coronary ligation showed that enalapril prevented the release of splenic monocytes and reduced blood monocytosis ( Figure 5 ). Notably, monocyte numbers in the infarct were reduced to levels seen in wild-type mice (wild type, 0.42ϫ10 6 Ϯ0.1ϫ10 6 ; apoE Ϫ/Ϫ , 1.23ϫ10 6 Ϯ0.1ϫ10 6 ; apoE Ϫ/Ϫ enalapril, 0.35ϫ10 6 Ϯ0.1ϫ10 6 ). The treatment reduced the number of both Ly-6C high and Ly-6C low monocytes ( Figure 5B ).
Wound healing was then assessed by histology on days 4, 7, and 10 after coronary ligation. Immunoreactive staining of the infarcted tissue from apoE Ϫ/Ϫ mice showed that enalapril supported the resolution of inflammation, because numbers of inflammatory cells, including monocytes, neutrophils, and macrophages were reduced ( Figure 6 ). We had previously found that the infarcts of apoE Ϫ/Ϫ mice contain more microvessels and less collagen, likely because of increased delivery of proangiogenic factors and proteases by monocytes. 18 This was reversed in the present study: enalapril decreased the number of neovessels and augmented collagen content in the border zone ( Figure 6 ). Thus, reduction of inflammation by enalapril improved infarct healing in apoE Ϫ/Ϫ mice.
Early ACE Inhibitor Treatment Reduces Protease Activity and Improves Left Ventricular Remodeling in ApoE ؊/؊ Mice With MI
We next evaluated the effects of improved healing in enalapril-treated mice on left ventricular remodeling. Infarct size and proteolytic activity were measured by FMT-CT 17 on day 1 after MI, followed by MRI on day 21 to evaluate left ventricular anatomy and function. A group of apoE Ϫ/Ϫ mice received 20 mg/kg enalapril (see flow chart in Figure 7 ) and was compared with untreated apoE Ϫ/Ϫ mice. Importantly, treatment was terminated on day 7 to study ACE inhibitor effects during the early healing phase after MI. CT imaging found that infarct size 35 on day 1 was similar between study groups. To assess infarct inflammation in vivo, we quantitated proteolytic activity in infarcts using an activatable fluorescent protease sensor and FMT-CT. 17, 30 Regions of interest were identified in the FMT dataset based on anatomic information provided by fusion with CT images. In line with flow cytometric results showing lower monocyte numbers, enalapril reduced proteolytic activity in the infarct (Figure 7 ; PϽ0.05). Enalapril therapy was discontinued on day 7, when inflammation in murine infarcts subsides and actions of the ACE inhibitor on the remote myocardium would predominate. Mice were then followed up on day 21 after MI by MRI volumetry. Untreated mice showed substantial left ventricular remodeling and a reduced ejection fraction. However, MRI parameters improved in the enalapril-treated cohort. These mice had higher ejection fractions and smaller end-diastolic volumes (Figure 7; PϽ0.05) . Increased scar thickness ( Figure  7 ; PϽ0.05) indicated that the treatment had influenced infarct healing, as infarct expansion and thinning is a hallmark of impaired healing. 15 Left ventricular mass was also reduced (Figure 7) .
When enalapril treatment was started 1 hour after coronary ligation, the strong antiinflammatory effects seen by FMT-CT were preserved (protease sensor activation: MI 67.6Ϯ17.0 pmol, MI enalapril 26.2Ϯ8.2 pmol, PϽ0.05). In the same mice, MRI derived ejection fraction on day 21 was higher when compared with untreated mice (control MI, 34Ϯ4%, MI enalapril 43Ϯ2%, PϽ0.05).
Early ACE inhibitor treatment has beneficial effects on left ventricular hemodynamics, and reduces local ACE activity in the heart. We wanted to explore to what extent the impact on the monocyte flux contributes to the overall benefits of enalapril. We thus neutralized the splenic monocyte reservoir by surgical removal of the spleen at the time of coronary ligation. As in enalapril-treated mice, this results in a reduced availability of splenic monocytes, but leaves nonspleen targets of enalapril untouched. Hence, this cohort models the isolated splenic effect of ACE inhibition. FMT-CT showed a similar reduction of protease activity in the infarct of apoE Ϫ/Ϫ mice by enalapril and splenectomy (Figure 7; PϽ0.05) . This is in line with the notion that both procedures reduce the recruitment of monocytes into the infarct, cells that are the major source of proteases in MI. 31 In apoE Ϫ/Ϫ mice, splenectomy had a beneficial effect on left ventricular remodeling, albeit to a lesser degree than treatment with enalapril ( Figure  7 ; PϽ0.05). Compared with untreated apoE Ϫ/Ϫ mice, the EF was improved by 9% in splenectomized mice, and by 16% in mice treated with enalapril. Similar trends were observed for the end-diastolic volume, left ventricular mass, and scar thickness, all measured by MRI (Figure 7 ).
IRI Is Increased in ApoE ؊/؊ Mice and Ameliorated by Enalapril and by Splenectomy
Most patients with acute MI reach the hospital in time for reperfusion therapy. We therefore investigated the role of monocytes in IRI. During 35 minutes of ischemia, mice were injected with fluorescent microspheres to delineate the area at risk. Twenty-four hours after reperfusion, infarct size was determined by TTC staining, and area at risk by fluorescence imaging of myocardial rings ( Figure 8A ). Compared with wild-type mice, the infarct/area at risk ratio was profoundly increased in apoE Ϫ/Ϫ mice ( Figure 8B ), and this was paralleled by an increased number of monocytes recruited to the injured myocardium ( Figure 8C and 8D) . Treatment with enalapril and surgical removal of the splenic monocyte reservoir reduced the infarct/area at risk ratio in a similar fashion. Likewise, the number of monocytes recruited to the heart was reduced in parallel by enalapril treatment and splenectomy ( Figure 8C and 8D) . Analysis of spleens revealed that enalapril inhibited the release of the splenic monocyte reservoir following IRI ( Figure 8E ). 
Discussion
In 2010, an estimated 785 000 Americans will have a new acute coronary syndrome, 1 every 25 seconds. 36 Most of these patients will receive ACE inhibitor therapy within 24 hours. Here, we identified a new mechanism that contributes to the beneficial effects of early ACE inhibitor therapy after MI. In mice with coronary ligation, enalapril decreased Ang II/AT 1 R signaling on monocytes in the spleen and thus inhibited their massive mobilization from the splenic reservoir. Preventing the release of splenic monocytes subsequently controlled their recruitment in infarcts, and short-term treatment during the wound-healing phase after MI had a profound long-term impact on left ventricular remodeling.
Coronary ligation in apoE Ϫ/Ϫ mice allows the study of MI in the context of preexisting chronic inflammation. 17 In these mice, hyperlipidemia induces a progressive increase of the monocyte pool. 37 The cells are recruited into the vessel wall, a process that is now well understood to drive atherosclerotic lesion formation and progression. 38, 39 We chose this model because it likely reproduces innate immune processes during infarct repair in humans, with higher fidelity than a model of coronary ligation in otherwise "healthy" wild-type mice, 34 because patients experience infarcts resulting from thrombotic complication of an atherosclerotic plaque. The preexisting heightened immune activity and the increased levels of blood monocytes at the time of MI result in enhanced recruitment of monocytes into the infarct. 17 Blood monocytosis by itself (ie, in the absence of atherosclerosis or hypercholesterolemia, but induced by LPS injections) causes excessive monocyte recruitment in infarcts, impaired infarct healing and accelerated left ventricular dilation. 17 Of note, a parallel relationship of increased blood monocyte levels and left ventricular remodeling was recently described in patients after MI. 21 In the present study, enalapril substantially reduced the mobilization of monocytes from the spleen and lowered their numbers in blood and infarct of wild-type, as well as apoE Ϫ/Ϫ , mice. Therefore, the antiinflammatory properties of ACE inhibition may mitigate the accentuated immune activity in patients with acute coronary syndromes and thus partly contribute to improving their prognosis. 19 -21 Histological assessment of enalapril-treated apoE Ϫ/Ϫ mice after MI showed faster resolution of inflammation, and normalization of wound-healing parameters such as number of neovessels and collagen content in the border zone. Direct action of Ang II on fibroblasts promotes collagen synthesis and ACE inhibition reduces collagen content in the remote zone 40, 41 and scar. 42 In the present study, we found increased collagen content in the scar of treated apoE Ϫ/Ϫ mice. Because enalapril drastically reduced numbers of inflammatory monocytes and protease activity, it likely changed the balance of matrix breakdown and synthesis. 43 Increased scar thickness measured by MRI indicates that improved healing reduced infarct expansion, which then resulted in attenuated left ventricular remodeling and higher ejection fraction in enalapril-treated mice. Anatomic and functional MR data measured 3 weeks after MI were improved although therapy was limited to the first week, suggesting that treatment during the early period of infarct healing garners long-term benefits. ACE inhibition has also been shown to modulate inflammatory cytokine expression, for instance TNF-␣ or TGF-␤, 8 which may influence left ventricular remodeling and heart failure. Because these regulators of innate immunity 14 are found in monocytes, it is likely that the effects of ACE inhibition on monocyte traffic, at least partially, contribute to a change in the regional cytokine milieu. This is supported by the 4.3-fold higher TGF-␤ mRNA levels in monocytes when compared with infarct tissue levels.
Similar as in previous reports which showed increased recruitment of monocytes to the infarct after permanent coronary artery occlusion in apoE Ϫ/Ϫ mice with atherosclerosis and blood monocytosis, 17 we found that monocyte recruitment is more than doubled after IRI in these mice. The majority of recruited cells belonged to the inflammatory Ly-6C high subset, which carry high payloads of potentially harmful inflammatory mediators. When compared with wildtype mice, the infarct size was increased in apoE Ϫ/Ϫ mice. Treatment with enalapril as well as splenectomy reduced the number of recruited monocytes and the quantity of infarcted tissue to levels seen in wild-type mice. The lower number of monocytes in heart tissue was attributable to inhibited splenic release following ACE inhibitor treatment. These findings position monocytes as therapeutic targets in IRI, and confirm that ACE inhibitors reduce infarct size 44 -46 in a model that accounts for the heightened activity of the immune system in atherosclerosis. 38 ACE inhibitor therapy has many reported targets, including beneficial systemic hemodynamic effects and decrease of Ang II tissue levels. 4 To study the relative contribution of splenic effects, we removed the splenic monocyte reservoir surgically in apoE Ϫ/Ϫ mice. Infarct protease activity was reduced to the same extent by splenectomy and enalapril, which suggests dominance of the splenic effects in the acute antiinflammatory properties of enalapril. Ejection fraction on day 21 after MI was improved partially when compared with enalapril treatment (9% versus 16% improvement over untreated mice with MI). It is important to stress that these beneficial effects of splenectomy were observed in apoE Ϫ/Ϫ mice, which recruit too many monocytes to the healing infarct. 17 In healthy individuals, the existence of a rapidly deployable reservoir of myeloid cells is likely an evolutionary advantage because it allows the immune system to respond to injury quickly. The spleen may have many favorable effects for wound healing, and health in general. This is highlighted by a study of veterans who lost their spleens from World War II injuries and consequently had an increased cardiovascular mortality. 47 Also, the wholesale removal of the organ may compromise other, not yet known, protective functions in infarct healing.
Current guidelines of the American College of Cardiology and the American Heart Association recommend that oral ACE inhibitor therapy should be initiated within the first 24 hours of suspected acute MI in patients without contraindications. If the observations of this study translate into humans, the treatment would also curb inflammation in patients with a raised level of immune activity attributable to coexisting atherosclerotic disease. The data presented here provide additional mechanistic insight into the mortality reduction by early ACE inhibitor treatment found in clinical studies (HEART, 48 SMILE 49 ) and suggest that systemic or local infarct inflammation may be an important therapeutic target for guiding therapy in individual patients. The level of inflammation in the infarct could be monitored by monocyte/ macrophage imaging. To this end, the phagocytic or inflammatory properties of myeloid cells could be harnessed for MR imaging. 50, 51 Alternatively, as in this study, a key monocyte function could serve as an imaging biomarker. We used fluorescence molecular tomography to quantify proteasedependent activation of an optical beacon in the myocardium, which can be accomplished with nuclear imaging in patients. 52 While these technologies have not yet been translated into clinical care, the level of circulating monocytes may offer an approximation for the number of cells in the infarct. However, this association needs to be confirmed in patients.
In conclusion, we show that ACE inhibitor treatment has a profound impact on the innate immune response after MI and that this newly discovered mechanism contributes substan-tially to the benefits of early ACE inhibitor therapy after MI. The inhibition of monocyte mobilization from their splenic reservoir represents a powerful antiinflammatory action that may have therapeutic implications beyond treatment of hypertension and heart failure.
